Why indeed? Invited commentary on: Why aren't depot antipsychotics prescribed more often and what can be done about it?

Advances in Psychiatric Treatment

Volumn 11, Issue 3, 2005, Pages 211-213

  Barnes, Thomas R E ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

ARTICLE; CLINICAL PRACTICE; DRUG SAFETY; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; HEALTH PERSONNEL ATTITUDE; HOSPITALIZATION; HUMAN; MEDICAL DECISION MAKING; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHYSICIAN ATTITUDE; PRESCRIPTION; RELAPSE; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

EID: 18844458854     PISSN: 13555146     EISSN: None     Source Type: Journal    
DOI: 10.1192/apt.11.3.211     Document Type: Article

References (13)

1. Barnes, T. R. E. & Curson, D. A. (1994) Long-acting depot antipsychotics: a risk-benefit assessment. Drug Safety, 10, 464-479.
2. Bowen, J. & Barnes, T. R. E. (1994) The clinical characteristics of schizophrenic patients consenting and not consenting to a placebo-controlled trial. Human Psychopharmacology, 9, 423-433.
3. Correll, C. U., Leucht, S. & Kane, J. M. (2004) Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. American Journal of Psychiatry, 161, 414-425.
4. Desai, N. M., Huq, Z., Martin, S. D., et al (1999) Switching from depot antipsychotics to risperidone: results of a study of chronic schizophrenia. The Schizophrenia Treatment and Assessment Group. Advances in Therapy, 16, 78-88.
5. Glazer, W. M. & Kane, J. M. (1992) Depot neuroleptic therapy: an underutilized treatment option. Journal of Clinical Psychiatry, 53, 426-433.
6. Godleski, L. S., Goldsmith, L. J., Vieweg, W. V., et al (2003) Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia. Journal of Clinical Psychiatry, 64, 119-122.
7. Hogarty, G. E., Schooler, N. R., Ulrich, R., et al (1979) Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Archives of General Psychiatry, 36, 1283-1294.
8. Leucht, S., Barnes, T. R. E., Kissling, W., et al (2003) Relapse prevention in schizophrenia with new generation antipsychotics. A systematic review and explorative meta-analysis of randomized controlled trials. American Journal of Psychiatry, 160, 1209-1222.
9. Patel, M. X. & David, A. S. (2005) Why aren't depot antipsychotics prescribed more often and what can be done about it? Advances in Psychiatric Treatment, 11, 203-211.
10. Robert, L. W. & Geppert, C. M. A. (2004) Ethical use of long-acting medications in the treatment of severe and persistent mental illness. Comprehensive Psychiatry, 45, 161-167.
11. Schooler, N. R. (2003) Relapse and rehospitalisation: comparing oral and depot antipsychotics. Journal of Clinical Psychiatry, 64 (suppl. 16), 14-17.
12. Svedberg, B., Backenroth-Ohsako, G. & Lützén, K. (2003) On the path to recovery. Patients' experiences of treatment with long-acting injections of antipsychotic medication. International Journal of Mental Health Nursing, 12, 110-118.
13. Ziguras, S., Lambert, T. J. R., McKenzie, D. P., et al (1999) The influence of client's ethnicity on psychotropic medication management in community mental health services. Australian and New Zealand Journal of Psychiatry, 33, 882-888.